Osteocalcin Regulates Arterial Calcification via Altered Wnt Signalling and Glucose Metabolism by Rashdan, Nabil A et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Osteocalcin Regulates Arterial Calcification via Altered Wnt
Signalling and Glucose Metabolism
Citation for published version:
Rashdan, NA, Sim, AM, Cui, L, Phadwal, K, Roberts, FL, Carter, R, Ozdemir, DD, Hohenstein, P, Hung, J,
Kaczynski, J, Newby, DE, Baker, AH, Karsenty, G, Morton, NM & MacRae, VE 2019, 'Osteocalcin
Regulates Arterial Calcification via Altered Wnt Signalling and Glucose Metabolism', Journal of Bone and
Mineral Research. https://doi.org/10.1002/jbmr.3888
Digital Object Identifier (DOI):
10.1002/jbmr.3888
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Journal of Bone and Mineral Research
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 16. Oct. 2020
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/jbmr.3888 
 
 Osteocalcin Regulates Arterial Calcification via Altered Wnt Signalling and 
Glucose Metabolism 
Nabil A Rashdan1, Alisia M Sim2, Lin Cui1, Kanchan Phadwal1, Fiona L Roberts1, Roderick 
Carter3, Derya D Ozdemir1, Peter Hohenstein1, John Hung3, Jakub Kaczynski3, David E. 
Newby3, Andrew H. Baker3, Gerard Karsenty4, Nicholas M Morton3, Vicky E. MacRae1 
1 The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush, 
Midlothian, Edinburgh, EH25 9RG UK. 
2 School of Chemistry, University of Edinburgh, Joseph Black Building, David Brewster Road, Edinburgh, EH9 
3FJ, UK 
3 Centre for Cardiovascular Science, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, 
EH16 4TJ, UK  
4 Department of Genetics and Development, College of Physicians and Surgeons, Columbia University, New 
York, New York 10032, USA. 
 
 
Funding sources: 
VEM, NR, PH & DDO: Biotechnology and Biological Sciences Research Council (BBSRC) in 
the form of an Institute Strategic Programme Grant (BB/J004316/1;BBS/E/D/20221657) 
MRD, DEN, AHB: British Heart Foundation (FS/12/84, CH/09/002; CH/11/2/28733) 
DEN: Wellcome Trust  (WT103782AIA) 
AMS: OPTIMA CDT PhD studentship 
 
 
 
 
 
 
 
 
 
This article is protected by copyright. All rights reserved.
 
 
 
 
 
 
Abstract. 
Arterial calcification is an important hallmark of cardiovascular disease and shares many 
similarities with skeletal mineralisation. The bone-specific protein osteocalcin (OCN) is an 
established marker of vascular smooth muscle cell (VSMC) osteochondrogenic trans-
differentiation and a known regulator of glucose metabolism. However, the role of OCN in 
controlling arterial calcification is unclear. We hypothesised that OCN regulates calcification 
in VSMCs and sought to identify the underpinning signalling pathways. Immunohistochemistry 
revealed OCN co-localisation with VSMC calcification in human calcified carotid artery 
plaques. Additionally, 3 mM phosphate treatment stimulated OCN mRNA expression in 
cultured VSMCs (1.72 fold; p<0.001). Phosphate-induced calcification was blunted in VSMCs 
derived from OCN null mice (Ocn-/-) compared to cells derived from Wild-Type (WT) mice (0.37 
fold, p<0.001). Ocn-/- VSMCs showed reduced mRNA expression of the osteogenic marker 
Runx2 (0.51 fold, p<0.01) and the sodium-dependent phosphate transporter, PiT1 (0.70 fold, 
p<0.001), with an increase in the calcification inhibitor Mgp (1.42 fold, p<0.05) compared to 
WT. Ocn-/- VSMCs also showed reduced mRNA expression of Axin2 (0.13 fold; p<0.001) and 
Cyclin D (0.71 fold; p<0.01), markers of Wnt signalling. CHIR99021 (GSK3β inhibitor) 
treatment increased calcium deposition in WT and Ocn-/- VSMCs (1 µM; p<0.001). Ocn-/- 
VSMCs however calcified less than WT cells (1 µM; 0.27 fold; p<0.001). Ocn-/- VSMCs showed 
reduced mRNA expression of Glut1 (0.78 fold p<0.001), Hex1 (0.77 fold p<0.01) and Pdk4 
(0.47 fold p<0.001). This was accompanied by reduced glucose uptake (0.38 fold, p<0.05). 
Subsequent mitochondrial function assessment revealed increased ATP-linked respiration 
(1.29 fold, p<0.05), spare respiratory capacity (1.59 fold, p<0.01) and maximal respiration 
(1.52 fold, p<0.001) in Ocn-/- versus WT VSMCs. Together these data suggest that OCN plays 
a crucial role in arterial calcification mediated by Wnt/β-catenin signalling through reduced 
maximal respiration. Mitochondrial dynamics may therefore represent a novel therapeutic 
target for clinical intervention. 
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Introduction. 
The pathological process of arterial calcification shows many similarities with that of 
physiological bone development and formation (1). Crucially, vascular smooth muscle cells 
(VSMCs), the predominant cell type responsible for blood vessel calcification, can undergo 
phenotypic transition to chondrocytic, osteoblastic and osteocytic cells in a calcified 
environment (2, 3). Furthermore, phosphate accelerates this phenotypic trans-differentiation, 
evident in the loss of characteristic smooth muscle markers and the development of 
osteoblastic features, such as the expression of Runx2, Pit-1 and osteocalcin (OCN), and 
osteocyte markers including sclerostin and podopladin (Pdpn/E11) (2, 3). Arterial calcification 
also involves the reciprocal loss of recognised calcification suppressors, such as inorganic 
pyrophosphate (PPi), matrix Gla protein (MGP) and fetuin A (4, 5). However, despite extensive 
investigations, the specific endocrine and molecular signalling mechanisms underpinning the 
arterial calcification process have yet to be fully defined. 
Osteocalcin, the most abundant non-collagenous protein in bone(6), plays a key role in 
physiological and pathological calcification. Vitamin K-dependent post-translational 
modification of OCN involves the ᵞ-carboxylation of three glutamic residues (Gla domain)(6), 
which confers OCN’s hydroxyapatite binding ability. Intriguingly, recent findings have indicated 
that insulin signalling in osteoblasts favours bone resorption by osteoclasts, with 
decarboxylation of OCN occurring in resorption lacunae(7), resulting in increased circulating 
undercarboxylated OCN and a positive feedback loop on glucose metabolism via pancreatic 
insulin secretion(8, 9). Furthermore, OCN locally shifts VSMCs towards the glycolytic 
breakdown of glucose, and stimulates VSMC calcification in vitro (10). However, the cellular 
mechanisms through which OCN mediates this action, and the precise role of glucose 
metabolism in VSMC calcification remains to be fully elucidated.  We have therefore 
undertaken analysis of clinical tissues in conjunction with in vitro studies in C57BL/6 and Ocn-
null (Ocn-/-) mice to investigate the functional role of OCN in glycolysis and arterial calcification. 
Materials and Methods. 
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Human tissues. 
Carotid artery plaque samples were obtained with appropriate ethical approval from patients 
undergoing carotid endarterectomy (Ethics Number: 15/ES/0094) and assessed subjectively 
for stability status. Research ethics committee approval (National Health Service Lothian 
Tissue Governance) and the written and informed consent of all participants were obtained. 
The samples were from three male patients, aged 54, 71, and 74. The first was a smoker with 
a history of chronic obstructive pulmonary hypertension. The second had a history of 
pancreatic cancer, hypertension, and hypercholesterolemia. The final patient had a history of 
myocardial infarction, pleural plaque, chronic obstructive pulmonary hypertension, severe left 
ventricular systolic dysfunction, and aortic stenosis. Human tissue was used in this study in 
conformation with the declaration of Helsinki.  
Materials. 
All materials unless stated otherwise were purchased from Sigma-Aldrich (Sigma, Dorset, 
UK). 
 
Mice. 
Ocn-/- mice were previously generated and genotyped as described (11). All animal 
experiments were performed under UK Home Office licensed approval in accordance with 
Directive 2010/63/EU of the European Parliament and were maintained in accordance with 
Home Office guidelines for the care and use of laboratory animals. C57BL/6 mice were 
supplied by Charles River Laboratories (Harlow, Essex, UK). 
Primary murine VSMC isolation.  
Primary aortic VSMCs were isolated from five-week old mice as described previously (3, 12, 
13). Mice were euthanized by cervical dislocation. The aorta was then dissected, the adventitia 
removed, and the aorta cut open to expose the endothelial layer. After washing with Hanks’ 
balanced salt solution (HBSS; Life Technologies, Paisley, UK), the aortae were cut 
longitudinally. Eight aortae were pooled together and incubated for 10 min at 37˚C in 1 mg/mL 
trypsin (Life Technologies, Paisley, UK) to remove any remaining endothelial cells Aortae were 
washed and incubated overnight at 37˚C in VSMC growth medium containing α-MEM, 10% 
foetal bovine serum and 1% gentamycin (Life Technologies, Paisley, UK) in a humidified 5% 
CO2 incubator. Tissues were then washed and then incubated in 425 UI/mL collagenase type 
II (Worthington Biochemical Corporation, Lakewood, NJ) for 4 hrs at 37˚C. The resulting cell 
suspension was centrifuged at 320g for 5 min. VSMC pellets were resuspended in culture 
medium and cultured for two passages in T25 tissue culture flasks (Corning Inc, Corning, NY) 
coated with 0.25 μg/cm2 laminin (Sigma, Dorset, UK) to promote maintenance of the 
contractile differentiation state(14). 
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Induction of calcification. 
VMSCs were seeded in growth medium at a density of 1 x 105 cells per well in 12 well plates 
(Corning Inc, Corning, NY). Calcification was induced as described previously (12, 15-17). In 
brief, cells were grown to confluence (day 0) and changed to calcification medium, which was 
prepared by supplementing growth medium with inorganic phosphate (Pi) to a final 
concentration of 3 mM. Cells were cultured in calcifying media for up to 7 days and media was 
changed every second/third day. All drugs and recombinant proteins were added at day 0. 
Determination of calcification. 
Calcium deposition was assessed as previously described (17, 18). Briefly, VSMCs were 
washed and incubated for 24 h in 0.6 N HCl at 4˚C. Free calcium was determined 
colorimetrically by a stable interaction with O-Cresolphthalein using a commercially available 
kit (Randox Laboratories Ltd., County Antrim, UK), and corrected for total protein 
concentration determined by DC assay (Bio-Rad Laboratories Ltd., Hemel Hempstead, UK).  
Histology and immunohistochemistry. 
Carotid artery plaques were dissected and fixed in 10% neutral buffered saline. Fixed tissues 
were dehydrated, embedded in paraffin wax and sectioned at 5 μm. Sections were de-waxed 
in xylene and stained with Von Kossa and nuclear fast red to visualise phosphate deposition 
or Alizarin red and counterstained with light green (Sigma, Dorset, UK) to assess calcium 
deposition. Sections were also stained with haematoxylin and eosin to assess tissue 
architecture. For Immunohistochemistry, sections were de-waxed in xylene followed by 
dehydration in graded alcohol. Antigen retrieval was accomplished using hot sodium citrate 
buffer (10 mM Sodium Citrate, 0.05% Tween 20, pH 6.0). Sections were then washed in Tris‐
Buffered Saline (TBS) and 0.025% Triton X-100 (wash buffer) (Sigma) and blocked in 5% 
normal goat serum and 1% BSA in TBS for 1 h. Following blocking slides were again washed 
and then incubated overnight at 4˚C with 4 μg IgG/mL anti-osteocalcin (sc-365797, Santa Cruz 
Biotechnology, Dallas, TX) in 1% BSA in TBS. Endogenous peroxidase was blocked by 
incubation in 0.3% H2O2 in TBS for 15 min. The sections were then washed, incubated with 
diluted biotinylated mouse IgG kappa binding protein (sc-517142, Santa Cruz Biotechnology, 
Dallas, TX) (1:50 dilution) in 1% BSA in TBS for 30 min. Sections were then washed twice, 
then incubated for 30 min with VECTASTAIN® ABC Reagent (Vector Labs, Peterborough, 
UK). The sections were then incubated with DAB substrate reagent (0.06% DAB, 0.1% H2O2 
in TBS) until the desired stain intensity developed. The sections were finally dehydrated, 
counterstained with haematoxylin and eosin and mounted in DePeX. Control sections were 
incubated with non-immune mouse IgG (4 μg IgG/mL) in place of the primary antibody. 
 
Analysis of gene expression. 
Total RNA was isolated using RNeasy mini columns (Qiagen, West Sussex, UK) following the 
manufacturer's directions. RNA was reverse transcribed and specific cDNAs were quantified 
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by real-time PCR using the SYBR green detection method as previously reported (19). 
Predesigned primers were purchased from Eurofins MWG Biotech (Ebersberg, Germany), 
Qiagen (Manchester, UK), Ambion (Cambridge UK) and Primer Design (Southampton, UK), 
with available sequences provided in the online Data Supplement (Suppl. Table S1).  
Measurement of glucose uptake. 
VSMCs were seeded at 10,000 cells per well in 96-well plates and incubated overnight. Cells 
were then cultured in calcifying medium for 48 h, followed by incubation in glucose-free DMEM 
(Life Technologies, Paisley, UK) for 1.5 hrs. VSMCs were then cultured with 5 mM fluorescent 
glucose analogue 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose (2-NBDG) 
(Life Technologies, Paisley, UK) for 20 min. Cells were then washed twice with phosphate 
buffered saline (Life Technologies, Paisley, UK).  Fluorescence was quantified at 485 nm 
excitation and 535 nm emission on a Synergy HT Multi Mode Microplate reader (BioTek, 
Swindon, UK) and corrected for total protein concentration (Bio-Rad Laboratories Ltd., Hemel 
Hempstead, UK).  
Measurement of respiration. 
VSMCs were seeded into XF24 V7 PS cell culture microplates (100777-004, Agilent 
Technologies LDA UK Limited) at ~20,000 cells per well. Cells were then cultured for 7 days 
with media changed every other day. On the day of respiratory analysis, cells were washed 3 
times with Seahorse XF assay medium (102365-100, Agilent Technologies LDA UK Limited) 
supplemented with 10 mM Glucose and 2 mM pyruvate, pH adjusted with NaOH to 7.35 at 
37°C. Cells were then incubated in a CO2-free incubator at 37˚C for 30 min. Following this 
incubation microplates were placed in a Seahorse XFe24 bioanalyser (Agilent Technologies 
LDA UK Limited).  After basal measurements of oxygen consumption rate (OCR), respiratory 
ATP synthesis was inhibited by injecting oligomycin (an ATP synthase inhibitor) at a final 
concentration of 1 µM, causing a drop in OCR representative of ATP synthesis-linked 
respiration. Next the electron transport chain was uncoupled from ATP synthesis by injecting 
1 µM final concentration of carbonyl cyanide 4- (trifluoromethoxy) phenylhydrazone (FCCP), 
increasing OCR to a state of maximal respiration. Finally, respiration was abolished by 
injection of rotenone and antimycin A (inhibitors of mitochondrial complexes I and III 
respectively). at a concentration of 1 µM each. ATP-linked respiratory OCR was calculated 
from the difference between basal and oligomycin inhibited OCR. The difference between 
basal OCR and FCCP induced OCR was used to calculate the respiratory reserve capacity. 
The difference in OCR between FCCP and rotenone/antimycin A was considered maximal 
respiratory capacity. Proton leak respiratory OCR was calculated from the difference between 
oligomycin inhibited OCR and rotenone/antimycin A inhibited OCR.  
Measurement of glycolysis. 
Extracellular acidification rate (ECAR) was used to estimate the glycolytic rate. VSMCs were 
cultured as above on XF24 V7 PS cell culture microplates. VSMCs were washed 3 times with 
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XF assay medium (without glucose or pyruvate) and incubated in a CO2-free incubator at 37˚C 
for 30 minutes. Glucose starved VSMCs were placed in a Seahorse XFe24 bioanalyser. After 
basal measurements were taken, glucose was injected to a final concentration of 10 mM. The 
increase in ECAR following addition of glucose is representative of the cellular glycolytic flux. 
Oligomycin was then injected to a final concentration of 1 µM, inhibiting respiration derived 
ATP leading to an increase in ECAR. This increase was considered the Glycolytic reserve. At 
this point 2-deoxyglucose to a final concentration of 100 mM was injected to inhibit glycolysis. 
Glycolytic capacity was calculated from the difference between the oligomycin induced ECAR 
and the 2-deoxyglucose induced decrease.  
Transfection assays. 
VSMCs were transfected with either 60 pmol of mouse β-catenin (Santa Cruz Biotechnology, 
sc-29210) or scrambled control SiRNA (Santa Cruz Biotechnology, sc-37007) with siRNA 
transfection reagent (Santa Cruz Biotechnology, sc-29528), according to the manufacturer’s 
instructions. The cells were harvested for experiments 72 hours post-transfection.  
Immunoblotting. 
Protein was extracted using radioimmunoprecipitation assay buffer supplemented with Halt 
Protease Inhibitor Cocktail EDTA-free (Thermo Scientific, 87785). Protein content was 
determined using Pierce™ BCA Protein Assay Kit (Thermo Scientific, 23225) and samples 
were boiled with 2X sample buffer and then separated on a 4–12% Bis-Tris gel (Invitrogen). 
Proteins were then transferred to PVDF membranes (Immobilon-FL transfer membrane, 
IPFL00010) and blocked for 1 hour in LICOR blocking buffer. The membranes were incubated 
in primary antibodies (1: 250 mouse monoclonal anti-β-catenin, Santa Cruz Biotechnology, sc-
7963, and 1:5000 Rabbit polyclonal anti-β-actin, GeneTex, GTX109639) in LICOR blocking 
buffer, at 4 °C overnight. Blots were then washed and incubated at first in goat anti-rabbit 
IRDye 680RD (926-68071) for 1 hour. Blots were then imaged using an Odyssey CLx Infrared 
Imaging System. The default settings used for blot image acquisition were resolution 169 μm, 
quality medium and laser intensities between 5–1.5. Blots were then incubated in goat anti-
mouse IRDye 680 RD (926-68070) (Licor, Cambridge, UK) for 1 hour and reimaged.  
 
 
Statistical analysis. 
All data are presented as mean ± S.D. Data were analysed by two sample Student’s t-test or 
one-way analysis of variance (ANOVA) followed by Tukey's range test, as appropriate. All 
statistical analysis was performed using Minitab 17 (Minitab Inc., Coventry, UK). p<0.05 was 
considered to be significant and p-values are represented as: *p<0.05; **p<0.01; ***p<0.001. 
n= individual cultures. 
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Results. 
OCN is expressed in human calcified carotid artery plaque.  
To investigate the role of OCN in arterial calcification, localisation studies were undertaken. 
Calcification of human carotid artery plaque was confirmed by Von Kossa (Fig. 1A (i & v)) and 
Alizarin red staining (Fig. 1A (ii & vi)). Immunohistochemistry confirmed OCN expression in 
calcified regions of the tissue (Fig. 1A (iii & vii)). Von Kossa (Fig. 1B (i & v)), Alizarin red (Fig. 
1B (ii & vi)) and OCN (Fig. 1B (iii & vii)) staining was absent in non-calcified regions. Hence, 
OCN localisation in human atherosclerotic plaques correlates with in situ calcification. 
Up-regulation of OCN during the VSMC calcification process. 
Since arterial calcification is highly correlated with elevated serum phosphate levels (20), 
VSMCs were cultured in growth medium containing 3 mM Pi. Three mM Pi induced an increase 
in VSMCs calcium deposition (determined by HCl leaching) by day 7 compared to cells 
cultured in control medium (2.26 fold, p<0.001; Fig. 1C). This was accompanied by an increase 
in Ocn mRNA expression (1.72 fold; p<0.001 Fig. 1D). Consistent with previous studies (16, 
17), 3 mM Pi induced osteogenic transition of VSMCs, as demonstrated by up-regulated 
expression of Runx2 (1.95-fold; p<0.01); and Pit-1 (7.18-fold; p<0.001) (Fig. 1E) while the 
calcification inhibitor Mgp (0.66-fold; p<0.01) was reduced by 3 mM Pi (Fig. 1E). These data 
suggest that Ocn expression of is positively regulated by elevated Pi.  
OCN ablation attenuates Pi-induced VSMC calcification. 
To establish the functional role of OCN in arterial calcification, further studies were undertaken 
using VSMCs derived from Ocn-/- mice. In the presence of 3 mM Pi medium for 7 days, a 
reduction in calcium deposition was observed in Ocn-/- VSMCs compared to Wild Type (WT) 
control cells, as determined by HCl leaching (0.37 fold, p<0.001; Fig. 1F). Consistent with 
these data, Ocn-/- VSMCs showed a reduction in the mRNA expression of Runx2 (0.51 fold, 
p<0.01), and Pit-1 (0.70 fold, p<0.001 (Fig. 1G), with a concomitant increase in the calcification 
inhibitor Mgp compared to WT cells (1.42 fold, p<0.05; Fig. 1G). This observation suggests a 
direct link between Ocn expression and VSMC calcification.  
OCN ablation diminishes Wnt signalling in calcifying VSMCs.  
The Wnt signalling pathway plays an established role in osteogenesis and can impact on 
arterial calcification (21, 22). In the present study, calcifying VSMCs showed increased mRNA 
expression of the Wnt targets Axin2 (2.84 fold; p<0.01), Cyclin d (1.87 fold; p<0.05) and 
dickkopf-related protein 1 (Dkk1; 2.61 fold; p<0.05) (Fig. 2A). Functionally, CHIR99021, a 
glycogen synthase kinase 3β (GSK3β) inhibitor and Wnt signalling activator, accelerated Pi-
induced VSMC calcium deposition from 1 nM (4.18 fold, p<0.01, Fig. 2B). Conversely, 
exogenous recombinant DKK1 (a Wnt signalling pathway inhibitor) reduced Pi-induced 
calcium deposition in VSMCs from a minimum concentration of 2.5 ng/mL (0.42 fold p<0.05; 
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Fig. 2C). Subsequent studies investigated whether alterations in Wnt signalling underpinned 
the pro-calcification role of OCN. Ocn-/- VSMCs showed reduced mRNA expression of Wnt 
signalling markers Axin2 (0.13 fold; p<0.001), Cyclin d (0.71 fold; p<0.01; Fig. 2D). 
Conversely, Dkk1 expression was increased (1.55 fold, p<0.05, Fig. 2D). Treatment with 
CHIR99021 increased calcium deposition in both WT and Ocn-/- VSMCs (1 µM; p<0.001; Fig. 
2E). However, CHIR99021-induced calcification was blunted in Ocn-/- VSMCs compared to 
WT (1 µM; 0.27 fold; p<0.001).  
Glucose metabolism regulated by OCN in calcifying VSMCs. 
Accumulating evidence suggests that aerobic glycolysis may be a characteristic feature of 
VSMCs osteogenic transdifferentiaton during the calcification process (23). We therefore 
determined the effects of VSMCs calcification on glucose uptake using the fluorescent glucose 
analogue 2-NBDG. Normalised fluorescence was increased by culture of VSMCs with 3 mM 
Pi for 7 days (1.98 fold, p<0.05) compared to control cells (Fig. 3A). Consistent with this finding, 
calcifying VSMCs showed increased mRNA expression of Glut1 (1.98 fold, p<0.01), the rate 
limiting enzyme of glucose metabolism Hex1 (2.65 fold, p<0.01) and Pdk4 (2.17 fold p<0.01) 
(Fig. 3B).  
Together, these data suggest increased glucose metabolism during Pi-induced VSMCs 
calcification. Therefore, further studies interrogating the consequences of altered glucose 
metabolism were undertaken using pharmacological inhibitors. Interestingly, the inhibition of 
glucose uptake with fasentin, a GLUT1 specific inhibitor, accelerated Pi-induced VSMC 
calcification (20uM, 72%, p<0.01; Fig. 3C). Similarly, the hexokinase inhibitor 2-deoxyglucose 
(2-DG), increased calcium deposition (100 µM; 97% increase, p<0.05; Fig. 3D). 
Dichloroacetate (DCA), a general pyruvate dehydrogenase kinase (PDK) inhibitor which 
increases pyruvate dehydrogenase PDH activity, decreased Pi-induced VSMCs calcification 
(1mM; 50%, p<0.05; Fig. 3E).  
A Seahorse XFe24 flux bioanalyser was used to evaluate glycolysis (Fig. 3G) as well as 
oxidative phosphorylation (Fig. 3H) in VSMCs cultured with or without 3 mM Pi. Three mM Pi 
induced a decrease in both glycolytic capacity (0.37 fold, p<0.001) and reserve (0.74 fold, 
p<0.05) (Fig. 3I). Calcifying conditions also decreased ATP-linked respiration (0.58 fold 
p<0.01), spare respiratory capacity (0.37 fold, p<0.05) and maximal respiration (0.49 fold, 
p<0.01) (Fig. 3J). Consistent with the critical key role of OCN in glucose uptake and 
utilisation(10), Ocn-/- VSMCs exhibited reduced 2-NBDG fluorescence compared to WT cells 
(0.38 fold, p<0.05, Fig. 4A). This decrease in glucose uptake was accompanied by a marked 
reduction in the mRNA expression of Glut1 (0.78 fold p<0.001), Hex1 (0.77 fold p<0.01) and 
Pdk4 (0.47 fold p<0.001) in calcifying Ocn-/- VSMCs compared to WT control cells (Fig. 4B). 
Ocn-/- VSMCs had higher rates of glycolysis (Fig. 4C) and oxidative phosphorylation (Fig. 4D) 
compared to WT VSMCs, indicative of increased energy demand. Ocn-/- VSMCs also had 
higher basal glycolysis (2.85 fold, p<0.05), glycolytic capacity (1.58 fold, p<0.001) as well as 
glycolytic reserve (1.43 fold, p<0.001) (Fig. 4E) compared to WT cells. ATP-linked respiration 
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(1.29 fold, p<0.05), spare respiratory capacity (1.59 fold, p<0.01) and maximal respiration 
(1.52 fold, p<0.001) (Fig. 4F) were increased in Ocn-/- versus WT VSMCs. β-Catenin 
knockdown (Fig. 5A) induced a significant decrease (0.42 fold, p<0.01) in β-catenin protein 
expression (Fig. 5B).  β-Catenin siRNA reduced the expression of the Wnt signalling markers 
Axin2 (0.78 fold; p<0.05), Cyclin d (0.73 fold; p<0.001; Fig. 5C). Comparable to osteocalcin 
ablation in VSMCs, β-catenin knockdown also induced a significant increase in glycolytic 
capacity (1.90 fold, p<0.05) as well as glycolytic reserve (1.42 fold, p<0.05) (Fig. 5C). 
Discussion.  
The osteoblast-specific protein OCN mediates crucial inter-organ communications. Indeed, 
the inactivation of OCN secreted in the bone ECM influences an extensive range of 
physiological processes outwith bone, including fat accumulation, skeletal muscle function, 
cognition and reproduction(24). This investigation addressed the hypothesis that OCN induces 
arterial calcification through mechanisms underpinned by decreased glycolysis. Our data have 
shown that the expression of Ocn is associated with arterial calcification ex vivo and in vitro. 
Moreover, we have shown that OCN may be directly involved in Wnt-driven VSMC calcification 
via the regulation of mitochondrial activity. Our work offers new insight into the role of OCN in 
cardiovascular disease and provides direct evidence to suggest that OCN contributes to the 
pathological process of arterial calcification. 
Our in vitro investigations revealed a notable up-regulation of Ocn with phosphate-induced 
VSMC calcification. Furthermore, a concomitant increase in the expression of Runx2, a 
recognized regulator of osteoblastic differentiation and matrix calcification of VSMCs, was 
observed. Indeed, there is a substantial body of evidence linking RUNX2 elevation with arterial 
calcification. RUNX2 has been detected in calcified atherosclerotic lesions in people (25-28) 
and is up-regulated in VSMCs undergoing transdifferentiation to osteochondrogenic cells in 
mouse models of arterial intimal calcification (29)  and medial calcification (30). Additionally, 
calcified VSMCs showed up-regulated expression of the sodium-dependent phosphate co-
transporter PiT-1. Increased PiT-1 expression leads to elevated intracellular phosphate and 
induces the osteogenic conversion of VSMCs (31). A parallel decrease in matrix Gla protein, 
an established inhibitor of arterial calcification (5, 32-36) was observed. 
Consistent with these findings, we report an association between OCN expression and 
calcified carotid plaques in patients. These data confirm and extend previous studies showing 
increased OCN expression in calcified carotid plaques (37, 38) and arterial lesions as they 
progress from fatty streaks to fibro-calcific plaques (39). Furthermore, previous clinical 
analyses have revealed circulating uncarboxylated OCN to be positively associated with 
coronary artery calcification (40).  
The utilization of the novel Ocn knockout mouse model was central to this investigation. The 
employment of VSMCs derived from this mouse line emphatically highlights a functional role 
for OCN in phosphate-induced arterial calcification. Additionally, the reduced expression of 
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both Runx2 and PiT-1 in Ocn-/- VSMCs reveals that OCN may regulate the osteogenic 
differentiation of VSMCs. Furthermore, our data suggest that OCN may mediate VSMC 
calcification through increased expression of the calcification inhibitor MGP.  
Mechanistically our data suggests that OCN induces calcification through the Wnt/β-catenin 
signalling pathway, corroborating and extending previous studies highlighting Wnt signaling 
as a key regulator of arterial calcification. Paracrine Wnt signals are activated via bone 
morphogenetic protein-2–induced Msx2 expression within calcified plaques in LDLR−/− mice, 
resulting in increased osteogenesis (41). Additional studies have shown that LDL receptor–
related protein 5 (LRP5) expression is upregulated at sites of osteogenesis in human 
degenerative valves (42) and that atorvastatin inhibits hypercholesterolemia-induced 
calcification of rabbit aortic valves by downregulating LRP5 and β-catenin levels (43). This 
study is the first to highlight the Wnt/β-catenin signalling pathway as a hub in driving OCN-
regulated arterial calcification.  
A potential link between OCN and glucose metabolism in calcifying smooth muscle cells has 
recently been suggested (10). This is consistent with recent seminal research showing OCN 
to be a key metabolic hormone inducing increased insulin production and sensitivity (8, 9). 
Ocn-/- VSMCs showed higher basal glycolysis and maximal respiration rates compared to WT 
VSMCs, which is indicative of these cells having greater energy demand, and increased ATP-
linked respiration. This in turn may inhibit calcification in an Ectonucleotide 
Pyrophosphatase/Phosphodiesterase 1(ENPP1)-dependent manner (44), whereby ENPP1 
converts ATP to pyrophosphate, a potent calcification inhibitor (45). Further studies employing 
pyrophosphate-deficient mouse models (e.g. Enpp1-/- and Abcc6-/- mice) are required to more 
fully investigate the role of pyrophosphate biogenesis as a key component of mitochondrial 
contributions to calcification downstream of this newly elucidated OCN /Wnt axis. 
In summary, we demonstrate a functional role for OCN in the pathological process of arterial 
calcification. Mechanistically, this role may be mediated by Wnt signalling and be dependent 
on decreased maximal respiration. To the best of our knowledge, this is the first study 
demonstrating an interaction between Wnt signalling and cellular metabolism within the 
context of VSMC calcification, highlighting new potential therapeutic strategies for the 
inhibition of arterial calcification. 
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Figure legends. 
Figure 1. Osteocalcin is expressed in calcified human cardiovascular tissue and plays 
a functional role in VSMCs calcification.  
 
A) Calcification of human carotid artery plaque was confirmed by (i & v) Von Kossa (arrows 
indicate positive Von Kossa staining) and (ii & vi) Alizarin red staining (arrows indicate positive 
Alizarin red staining). (iii & vii) OCN expression was observed in the plaque around the area 
of calcification (arrows indicate positive OCN staining) (iv and viii) IgG control. B) Non-calcified 
human carotid artery plaque was negative for (i & v) Von Kossa, (ii & vi) Alizarin red staining. 
(iii & vii) OCN expression (iv and viii) shows IgG control. VSMCs were cultured with 3 mM Pi 
or control (1 mM Pi) for 7 days. C) VSMCs calcium deposition (determined by HCL leaching) 
in cells cultured in 3 mM Pi compared to cells cultured in control medium. D) Ocn mRNA 
expression E) 3 mM Pi induced the expression of osteogenic markers Runx2, Pit-1, while, 
Mgp was significantly reduced by 3 mM Pi. F) Calcium content (µg/mg protein) by HCl leaching 
in  Ocn-/- (white bar) and WT (filled bar) VSMCs were cultured with control (1 mM Pi) or high 
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phosphate (3 mM Pi) medium for 7 days. G) Relative change in osteogenic marker mRNA 
expression of Ocn-/- cells compared to WT cells; Runx2 Pit1, and Mgp. Scale bars= 50 μm. 
Results are presented as mean ±S.D. p vs. control, (n=6).  
 
Figure 2. Wnt signalling contributes to VSMCs calcification and is decreased in 
calcifying Ocn-/- VSMCs. 
VSMCs were cultured with control 1 mM Pi or 3 mM Pi medium for 7 days. A) Fold change in 
the mRNA expression of Wnt signalling targets Axin2, Cyclin d, and Dkk1. Calcium content 
(µg/mg protein) was quantified in VSMCs cultured in 3 mM Pi medium in the presence/absence 
of B) CHIR99021 (Wnt activator) (0.001-10 μM) and C) DKK1(Wnt inhibitor) from 2.5 - 10 
ng/ml. D) Fold change in the mRNA expression of Axin2, Cyclin d  Dkk1 in Ocn-/- (square) and 
WT (circle) VSMCs after 7 days in 3 mM Pi medium. E) Calcium content (µg/mg protein) was 
quantified in Ocn-/- and WT VSMCs cultured in 3 mM Pi medium in the presence/absence of 
CHIR99021 0.1 – 10 μM. Results are presented as mean ±S.D. p vs. WT, (n=6).  
 
Figure 3. Glucose uptake and metabolism in calcifying VSMCs. 
VSMCs were cultured with control or 3 mM Pi medium. A)  Normalised fluorescence of the 
glucose analog 2-NBDG (fl/mg protein) determined after 48 hrs in culture (n=6). Fold change 
in the mRNA expression of glucose metabolism genes determined after 7 days in culture, B) 
Glut1, Hex1, and Pdk4 (n=6). Calcium content (µg/mg protein) was quantified in the 
presence/absence of: C) Fasentin (20-60 µM) induced calcification (n=6). D) 2-Deoxyglucose 
(1-100 µM) increased calcium content at 100 µM (n=6). E) DCA (0.1-10 mM) induced a 
significant reduction in calcium content from 1 mM (n=6). G) Extracellular acidification rate 
(ECAR) in control (white squares) and 3 mM Pi (black diamonds) cultured VSMCs during a 
glycolysis stress test (n=5). H) Oxygen consumption rate (OCR) in control (white squares) and 
3 mM Pi (black diamonds) cultured VSMCs during a mitochondrial stress test (n=5). I) 
Glycolytic capacity and reserve were significantly decreased by 3 mM Pi (squares) compared 
to control (circles) (n=5). J) ATP-linked respiration, spare respiratory capacity and maximal 
respiration were also significantly decreased by 3 mM Pi (squares) compared to control 
(circles). Results are presented as mean ±S.D. p vs. control.  
 
 
Figure 4. Altered glucose metabolism in calcifying Ocn-/- VSMCs. 
Ocn-/- and WT VSMCs were cultured with control or 3 mM Pi medium for up to 7 days. A) 
Normalised fluorescence of the glucose analog 2-NBDG (fl/mg protein) (n=8). B) Fold change 
in the mRNA expression of glucose metabolism genes in WT (circle) and Ocn-/- (square) Glut1, 
Hex1, and Pdk4 (n=6). C) ECAR during glycolysis stress test for WT (white squares) and Ocn-
/- (black diamonds) VSMCs D) OCR during mitochondrial stress test for WT (white squares) 
and Ocn-/- (black diamonds) VSMCs (n=6). E) Basal glycolysis, glycolytic capacity and 
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glycolytic reserve were significantly higher in Ocn-/-  VSMCs (square) compared to  WT (circle) 
(n=5). F) ATP-linked respiration, spare respiratory capacity and maximal respiration were also 
significantly higher in Ocn-/- VSMCs (square) compared to WT (circle) (n=5). Results are 
presented as mean ±S.D. p vs. WT. 
Figure 5. Altered glucose metabolism by β-catenin knockdown in VSMCs. 
WT VSMCs were transfected with either scrambled or β-catenin siRNA. A) After 72h cellular 
β-catenin protein content was determined by western blot. B) Fold change in β-catenin protein 
compared to scrambled siRNA control (n=3). C) Fold change in the mRNA expression of 
Axin2, Cyclin d in β-catenin compared to scrambled siRNA treated VSMCs (n=5). C) ECAR 
during glycolysis stress test for scrambled (white squares) and β-catenin (black diamonds) 
siRNA treated VSMCs (n=9). D) Glycolytic capacity and glycolytic reserve were significantly 
higher in in β-catenin (square) compared to scrambled (circle) siRNA treated VSMCs (n=9). 
Results are presented as mean ±S.D. p vs. scrambled siRNA.  
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